Results 211 to 220 of about 89,205 (311)

A culturally tailored iSupport model for dementia carers: Study protocol for a hybrid type I randomised controlled trial. [PDF]

Int J Nurs Stud Adv
Yan Z, Xiao L, Tran K, Milte R, Meyer C, Chang HCR, Ullah S, Laver K, Yu Y, Kitson A, Low LF, Brodaty H, Chudecka A, Rittinghausen N, Efthymiou A, Ulate MM, Turana Y, Kristian K, Fiordelli M, Sinclair R, Kyriazopoulos H, Pot AM.   +21 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Review of Survey activities 2015: aFieldWork – an Android app for offline recording of geological information and data display [PDF]

Geological Survey of Denmark and Greenland Bulletin, 2016
M. Hansen, M.N. Petersen, T.F. Kokfelt , B.M. Stensgaard   +3 more
doaj  

Unravelling progress: how US foreign aid cuts undermine global efforts to end violence against women. [PDF]

BMC Public Health
Stern E, Doyle K, Levtov R, Heise L.
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Review of Survey activities 2015: Placing Greenland ice sheet ablation measurements in a multi-decadal context [PDF]

Geological Survey of Denmark and Greenland Bulletin, 2016
D. van As, R.S. Fausto, J. Cappelen, R.S.W. van de Wal, R.J. Braithwaite, H. Machguth, C. Charalampidis, J.E. Box, A.M. Solgaard, A.P. Ahlstrøm, K. Haubner, M. Citterio, S.B. Andersen   +12 more
doaj  

Exploring barriers to and experiences of palliative and end-of-life care for people living with HIV: a cross-sectional survey. [PDF]

BMJ Open
Crooks J, Simpson-Greene C, Hughes L, Dreja L, Tweed M, Holt T, Brimacombe M, Jeneway R, Macrowan R, Hudson BF.   +9 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Review of Survey activities 2013: 125 years of geological research for society [PDF]

Geological Survey of Denmark and Greenland Bulletin, 2014
Fredericia, J.
doaj  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source